Zealand Pharma A/S (OTCMKTS:ZLDPF) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eight analysts that are currently covering the stock, MarketBeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and three have issued a strong buy recommendation on the company.

ZLDPF has been the subject of several analyst reports. BNP Paribas Exane lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 6th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Zealand Pharma A/S in a research report on Thursday, June 4th. Cantor Fitzgerald restated a “neutral” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. Finally, William Blair restated a “market perform” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th.

Get Zealand Pharma A/S alerts:

Check Out Our Latest Stock Report on ZLDPF

Zealand Pharma A/S Stock Performance

Shares of OTCMKTS:ZLDPF opened at $44.70 on Tuesday. The stock has a market capitalization of $3.20 billion, a P/E ratio of 3.32 and a beta of 0.86. Zealand Pharma A/S has a 1-year low of $35.93 and a 1-year high of $83.12. The company has a current ratio of 37.17, a quick ratio of 37.17 and a debt-to-equity ratio of 0.02. The business has a 50-day moving average price of $47.94 and a two-hundred day moving average price of $57.76.

Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.87) earnings per share for the quarter, topping the consensus estimate of ($1.37) by $0.50. The firm had revenue of $5.33 million during the quarter, compared to analysts’ expectations of $2.81 million. Zealand Pharma A/S had a return on equity of 41.80% and a net margin of 68.82%. Equities analysts predict that Zealand Pharma A/S will post 2.37 earnings per share for the current year.

About Zealand Pharma A/S

(Get Free Report)

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.

Further Reading

• Five stocks we like better than Zealand Pharma A/S
• These 5 Companies Just Made a Massive Bet on Themselves
• 5 Stocks Built to Thrive in a Higher-for-Longer Economy
• RH’s Strong Q1 Still Leaves Investors With One Big Question
• Iran Ceasefire or Not, These 3 Companies Could Win

Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.